NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

ASCO LBA (NOT DCVAX-L RELATED)

https://meetinglibrary.asco.org/record/98443/abstract

Session: Developmental Therapeutics - Immunotherapy:

Authors:
Vivek Subbiah, Ravi Murthy, Omar Kayaleh, Marnix Leo Bosch; The University of Texas MD Anderson Cancer Center, Houston, TX; M. D. Anderson Cancer Center, Orlando, Orlando, FL; Northwest Biotherapeutics Inc, Bethesda, MD

Local and systemic antitumor effects of activated autologous dendritic cells for intratumoral injection: A phase I/II trial.

Background:
Dendritic cells (DC) are antigen presenting cells proficient in inducing de novo immune responses, and the presence of intratumoral DCs confers a survival advantage to patients, likely due to an improved balance between the immune system and the growing tumor lesion. We have initiated a Phase I/II clinical trial to exploit this finding, by using partially activated autologous DCs (aDC; DCVax-Direct) for intratumoral injection in inoperable tumors for which limited treatment options exist. These aDC retain antigen uptake and presentation capability and are conditioned to complete the maturation process following injection, resulting in initiation of a broad anti-tumor immune response. Preclinical animal data have demonstrated that these aDC can mobilize both local and systemic immune responses, and effectively clear both injected (local) and non-injected (distal) inoperable tumor lesions.